3 completed, 2 active not recruiting, 2 recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Skin Squamous Cell Carcinoma: new trials by email Literature Review of Skin Squamous Cell Carcinoma trials Research Report on Skin Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration - Cutaneous Melanoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 100 | 2023-12-19 | 2026-03-10 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Avelumab, Cetuximab - Skin Squamous Cell Carcinoma, Metastatic Skin Cancer | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 60 | 2019-06-17 | 2026-06-02 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-04-07 | 2025-05-28 |
| Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Pembrolizumab - Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma | Phase 2 | Completed | Emory University | 11 | 2017-01-27 | 2024-06-26 |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
Carcinoma, Merkel Cell (3) · Melanoma (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma, Mucinous (1) · Adenocarcinoma, Papillary (1) · Anus Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Signet Ring Cell (1) · Carcinoma, Squamous Cell (1)
Carcinoma (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Carcinoma, Neuroendocrine (3) · DNA Virus Infections (3) · Infections (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3)
Biopsy (2) · Specimen Handling (2) · pembrolizumab (2) · Cetuximab (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · Lidocaine, Prilocaine Drug Combination (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · ON 01910 (1) · X-Rays (1) · atezolizumab (1) · avelumab (1) · cobimetinib (1)
Alliance for Clinical Trials in Oncology (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Traws Pharma, Inc. (1)
United States (7)
Carlo M Contreras, MD (1) · Dan P. Zandberg, MD (1) · Kanwal P Raghav (1) · Michael Kurman, MD (1) · Michael Lowe, MD, MA (1) · Yanyan Lou, MD, PhD (1)
P30CA138292 (1), U10CA180821 (1), UM1CA186709 (1), UM1CA186716 (1)